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1 INTRODUCTION 
The topiC of parallel importation and the issues facing South Africa in that 
regard, are to be dealt with for purposes of this article against the back-
ground of the Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) and in the context of the recent South African legislation in the 
medical field. In this contribution, the objective or end goal is not in the first 
place to arrive at a solution to a problem, but rather to bring about a 
thorough understanding of the problem in all its theoretical complexity and 
practical implications. In this contribution the emphasis will therefore first be 
on the identification and analysis of the various features of the concept of 
parallel importation and different related legal principles, and secondly it will 
focus on the way in which these issues became relevant in the recent 
medicines legislation. 
2 PARALLEL IMPORTATION DEFINED 
Parallel importation is generally defined as the unauthorised importation into 
and sale in a country where an applicable intellectual property right exists, 
of genuine goods embodying the subject matter of the intellectual property 
OP) right and first put onto the market in another country by or with the 
consent of the right holder. 
This may be illustrated by way of example: 
Example 1 
A patentee P owns a patent in country A in respect of a pharmaceutical X. 
The pharmaceutical was developed after extensive research work had been 
done by p's R&D section, and was finally accepted and registered to be 
marketed after extensive clinical trials had been conducted to the satisfaction 
of the relevant Medicines Registration Authority. All of this took several years 
I See in general Bennett and Newcomb 1998: 62: Zadra·Symes and Basista: 1998: 219: Van 











































LAW, DEMOCRACY &. DEVELOPMENT 
of dedicated work, and cost a substantial amount of money. The patentee P 
also owns a patent in respect of the same pharmaceutical X in a second 
country B, where P conducts a manufacturing operation manufacturing the 
pharmaceutical X. For the sake of the example, assume that manufacture in 
A is expensive, and in B is cheap, If a trader T should purchase the pharma-
ceutical X from P in country B and endeavour [Q import the pharmaceutical 
into country A, that would amount to parallel importation, An attempt will 
be made further below to explain why such importation could constitute a 
problem for the patentee P in country A and could in fact be regarded as an 
infringement of P's patent rights in country A, so that patentee P may 
endeavour to prevent such importation, 
A number of variations may be introduced into the example without 
derogating from the principle of parallel importation, 
Example 2 
Thus, in the second country B,' the patentee P may have granted a non-
exclusive licence to a licensee L who conducts the manufacturing and 
marketing operations in return for a royalty paid to P. Should the trader T 
purchase the pharmaceutical X from the licensee L, the pharmaceutical 
would still have been put onto the market with the consent of the patentee 
P so that the goods are genuine; importation thereof into country A by the 
trader T would amount to parallel importation. 
Example 3 
In another variation, the patentee P may hold no parent in country C, but 
may himself put the pharmaceutical X manufactured by him in country A or 
elsewhere on to the market in country C via a wholesaler W, where it is 
bought by the trader T. The selling price in country C may be cheaper than 
in A because of price control in C. Should the trader T endeavour to import 
the pharmaceutical X into the country A, this would again constitute parallel 
importation. 
Up to now, no view has been expressed on whether or not the parallel 
importation will constitute an infringement of the patent rights of the 
patentee P. Good arguments can be advanced in support of either viewpoint. 
Example 4 
However, the position would be different where in the latter case of country 
C where no patent exists, a pharmaceutical Y identical or substantially similar 
to X were to be manufactured and sold to the trader T not by P (or his 
licensee L), but by an independent third party Q. In this case the pharmaceu-
tical Y is an infringing product, and importation of the pharmaceutical Y into 
country A would not amount to parallel importation but would constitute an 
infringement of the patent rights in country A and as such importation could 
be prohibited by the patentee P. 
The series of scenarios sketched above all had to do with patent rights. The 










































THE TRIPS AGREEMENT AND SOUTH AfRICAN LEGISLATION 
3 WHY PARALLEL IMPORTATION? 
The question should be asked, from the African perspective, why parallel trade 
issues could become relevant to independent countries on the African 
continent where the principle of free movement of goods as applies in Europe 
finds no or only limited application, The answer is to be found in the existence 
of price differentials' for example between countries where price regulation or 
restriction exists in one country and not in the others, [Watts & Treacy 1997: 
28 30] or where IP rights exist in one country (leading to price increases for 
example as a result of royalty payments) and not in the others, 
On the African continent, but also elsewhere, this is particularly true in the 
pharmaceutical field, Parallel importation issues have in the past been 
particularly prevalent in the pharmaceutical industry, and a number of 
possible reasons have been identified: 
• The development and refinement of new pharmaceutical products require 
substantial research and development expenditure. [Kolker 1997] These 
expenses have to be recovered, giving rise to higher product pricing in 
those countries that can afford to carry such pricing. 
• Pharmaceuticals are small volume products that can be moved between 
countries relatively easily. [Watts & Treacy 1997: 30) 
• Once the pharmaceutical product has been developed to the marketable 
stage, it can be copied and reproduced relatively easily and at relatively 
low cost (when compared to the high cost of the initial research work and 
subsequent clinical tests). 
• The demand for treatment means that specific pharmaceuticals creates 
a ready market which is sensitive (Q price differentials, particularly in 
those countries where funding for health care services is inadequate. 
• Because governments in some countries endeavour to reduce expenditure 
on specific products to enable available health care funds to be spread 
over a wider area, price controls exists, and resultant price differentials 
provide an environment conducive to parallel imports. 
Generally speaking the latter situation provides the incentive to the parallel 
trader: price differences in respect of the same product sold in different 
countries are necessary to create the right scenario for parallel imports. The 
parallel trader is induced to use the price difference to generate a trading profit. 
One should visualise the following chain of trading actions: [Senior 1996 27] 
• Conventional trading route: 
A patentee P owns a patent for a specific pharmaceutical X in the country 
A where no price controls exist, where manufacturing costs are relatively 
high, and where P intends to recover his research and development 
expenditure through sales of the pharmaceutical X, The result is that the 
pharmaceutical is manufactured by P and sold at say S 1 00 per unit to a 
wholesaler WA. The wholesaler WA adds his profit and re-sells to the 










































LAW, DEMOCRACY & DEVELOPMENT 
retail pharmacist Q at a unit price of say $ 120. The pharmacist Q adds his 
profit percentage and an amount for dispensing, so that the patient pays 
a unit price of say $ 140. 
• Parallel trading route: 
The patentee P also has a manufacturing operation in country B, where 
he holds no patent and no price controls exist, but manufacturing costs 
are low, so that the same pharmaceutical X can be sold to a local whole-
saler WB at a unit price of $50, A parallel trader T in turn purchases from 
WB at a unit price of $60, imports into country A and sells to the whole-
saler we at $80, who can supply the pharmacist Q at a unit price of $ 1 00. 
Naturally the competitive situation which has now arisen, in terms of 
which the patentee P has to compete with his own product which arrived 
along a parallel trade route, is unacceptable to P; P would like to prevent 
importation into country A of the pharmaceutical X manufactured by him, 
p. in country B. 
The position may in fact be aggravated if the parallel trader T and the 
wholesaler we, realising that their competitor patentee P in country A 
cannot sell at under $ 1 00 without losing, and wholesaler WA cannot sell 
under $ 120, decide to increase the unit price to the pharmacist Y to say 
$ I 10. This means that a 'greater share of revenue goes to the parallel 
trading chain, while the patentee P earns from his manufacturing opera-
tor in country B only the lower controlled price. This represents a direct 
loss of revenue to the patentee P, as well as loss of sales to the wholesaler 
WA. At the same time, the patient is unlikely to receive any benefit from 
the potential lower priCing struCture. 
4 PARALLEL TRADE: MARKET CORRECTION OR MARKET 
DISTORTION? 
The question whether parallel trade serves in practice to correct markets, or 
has the effect of distorting markets, will elicit different responses, depending 
upon the interest and position of the respondent. [Senior 1996: 27] In cases 
of parallel trade, revenue is diverted to the trader, the importing wholesaler, 
and even to the pharmacist. While revenue is diverted away from the 
patentee/manufacturer, the benefit does not necessarily reach the patient, 
nor does any benefit accrue to government health care institutions or funds. 
The parallel trader who benefits, does so without in any way adding any 
value to the product or to the service provided to patients. 
Two principles are usually relied upon to justify parallel importation. 
However, it is difficult to understand how a principle such as the free 
movement of goods, which principle deprives the patentee of the full effect 
of his territorial patent right, namely to prohibit importation also of genuine 
goods into a country where he holds a patent, and a principle such as the 
exhaustion of rights when applied on an international scale, can be relied 
upon to justify and legalise a parallel trading system in terms of which 











































THE TRIPS AGREEMENT AND SOUTH AFRICAN LEGISLATION 
5 IMPORTATION AND INTELLECTUAL PROPERTY RIGHTS 
The instances of parallel importation exemplified above relate to intellectual 
property rights and appear to interfere with the exercise by the right holder 
of his IP right. Parallel importation as a phenomenon can manifest itself in 
all of the ar~as traditionally forming part of the field of intellectual property 
law, namely: 
• patent law; 1 
• design law;' 
• copyright law;' 
• trade mark law.' 
The IP rights derived in terms of the abovementioned four "laws" tradition-
ally have a territorial effect:' the right holder in each case is given the 
exclusive right to prohibit others from exploiting the subject matter of his 
right in the country in which the right was granted. The right to prohibit 
others from importing goods embodying the subject matter of the right 
forms, to a greater or lesser degree, part of the exclusive right granted to the 
right holder, depending on the particular IP right. 
For purposes of this article, we will concentrate only on the position in the 
area of patents. 
In South Africa the relevant provisions are the following: 
• Patents Act 57 of 1978: Section 45( 1) (as amended in 1997) provides that 
the effect of a patent shall be to grant to the patentee the right to exclude 
other persons from making, using, exercising, disposing or offering to 
dispose of. or importing the invention, so that the patentee shall have and 
enjoy the whole profit and advantage accruing by reason of the invention. 
This is in line with Article 28 of TRIPS: This article provides that a patent 
shall confer on the owner/patentee the exclusive rights to prevent third 
parties not having (he owner's consent, from (he acts of making, using, 
selling or offering for sale, or importing for these purposes the patented 
product; or, where the subject matter of the patent is a process, the product 
obtained by the process. Article 28 has a footnote' in terms of which the 
exclusive right of importation of the patentee is made subject to Article 6 of 
TRIPS, an aspect to be reverted to further below. 
It will be noted that the exclusive right given to the patentee appears to be 
an absolute right, namely the right to prevent unauthorised importation by 
others of the protected goods regardless of whether such goods are genuine 
, goods or infringing goods. The comparable provisions in the Copyright and 
3 Regulated in South Africa by (ile Patents Act 57 of 1978. 
4 Regulated in South Africa by the Designs Act 195 of 1993 
5 Regulated in South Africa by the Copynght Act 98 of 1978. 
6 Regulated in South Africa by the Trade Marks Act 194 of 1993. 
7 Senion 45 Patems Act: section 20 Designs Act: sections 6-1 I, 1 I A and liB Copyright ,i\Cl. 
8 Agreement on Trade,Related Aspects of Intellectual ProperlY Rights 1994 being one of the 
package of instruments which constitute the WTO/GATT 










































LAW, DEMOCRACY & DEVELOPMENT 
Trade Marks Acts have not been formulated in such wide and absolute 
terms. 'O Accordingly, as regards the control of importation, the IP right holder 
in South Africa in all cases has the right to control (eg to prohibit) the 
importation of infringing goods. However, it is only in the case of patents and 
designs that the right holder has a clear right to control (eg to prohibit) 
parallel importation, that is the importation of genuine goods. 
6 IMPORTATION RIGHT AND TERRITORIALITY 
It is important to bear in mind that a patent has only territorial effect." Up 
to now, and despite various efforts to create a so-called world patent, an 
inventor generally has to acquire separate patents to obtain patent rights in 
different countries. (It may be mentioned that a number of regional patent 
systems exist; this does not detract from the relevance of territoriality in the 
context of parallel importation.) A patentee can therefore enforce his patent 
rights only within the territory for which the patent has been granted, by 
preventing exploitation by others of the patented invention within the 
territorial borders, and by preventing importation by others of the patented 
product into the territory concerned. 
Consequently, taking into account the territoriality of IP laws, and the clear 
rights afforded the IP right holder at least in the cases of patents and designs, 
one would expect that a clear principle would apply, namely that the right 
holder would be entitled to prohibit the importation of goods falling within 
the scope of his right, regardless of whether the goods were genuine or 
infringing articles. As we shall see, this is not always the case in practice. In 
fact, for a variety of reasons as will be considered below, the principle of 
territoriality and the right to control importation have been eroded. 
7 PRINCIPLE OF THE EXHAUSTION OF RIGHTS 
The doctrine of the exhaustion of rights," and the question exactly how and 
to what extent it should find application in IP laws, are not as straightforward 
as one may expect, and in fact pose some complex questions. On a domestic 
level, the doctrine is based on the principle that once an IP right holder has 
manufactured a product in accordance with his IP right and has introduced 
it into the market by disposing thereof without restriction, such as to a 
purchaser, that purchaser can deal with the article further as he pleases, for 
example by re-selling it. The right holder is said to have exhausted his right. 
In the context of patent law, the principle of exhaustion can be explained 
in the following manner: The grant of a patent is a guarantee that the 
patentee, as a reward for the creative effort in creating a new invention, has 
the exclusive right to explOit the invention by manufacturing products 
embodying the inventive concept and putting them into circulation for the 
10 See section 23(2)(a) Copyright Act; section 34(2)(d) Trade Marks Act. Section 20( 1) of the 
Designs Act is similar to section 45( I) of the Patents Act. 
1 I See section 45 Patents ACE; Van Melle: 80. 










































THE TRIPS AGREEMENT AND SOUTH AfRICAN LEGISLATION 
First time. either directly by his own manuFacture or indirectly through a 
licensee (the quid pro quo principle). [Why brow 1997 43] Once the patentee 
has had the benefit of placing the product on the market without any 
restriction on the buyer, his right in respect of [hat article is said to have been 
exhausted. This principle is to be Found in section 45(2) of the South African 
Patents Act 57 of 1978. which provides that the sale of a patented article by 
or on behalF of the patentee or his licensee shall give the purchaser the right 
to use and dispose of that article. 
It would thus be seen as incompatible with the exhaustion principle to 
allow a patentee to rely on his patent to prevent further dealing with (ie 
importation) and further sale (ie of the product that he had initially 
marketed, or which had been marketed with his consent. The exhaustion 
principle has been formulated in substantially similar terms in its application 
to other IP fields, such as copyright law and trade mark law. 
Whereas the exhaustion principle is accepted as good law on the domestic 
level, it is not clear to what extent it can be said to apply internationally. 
[Whybrow 1997: 42] In other words. once an IP right holder has placed goods 
embodying the subject matter of the right, for example the inventive concept 
covered by the patent, on the market in country A, can it be said that he has 
exhausted his rights also in country B where he holds a similar IP right? Will a 
purchaser of the goods in country A be free to import those goods into country 
B? On the basis of the territorial principle discussed above, such importation 
should not be permissible, at least not in the case of patents. Furthermore, 
where a right holder has an IP right in country A. and places goods embodying 
the subject matter of the right on the market in country C where he holds no 
IP right. can it be said that his right has been exhausted in country C even 
though he holds no right there, so that he will be unable to prevent a trader 
from purchasing the goods in country C and importing the goods into country 
A? The answer to these questions is not clear. mainly because the principles of 
territoriality of IP rights and exhaustion of IP rights have been eroded or at least 
obscured by other considerations related to the gJobalisation of IP laws. such 
as the principle of the free movement of goods." 
An example of this globalisation effect is to be found in the European 
Union (EU). where a multi-state regional political organisation has been 
established within the wider borders of which the principle of the free 
movement of goods (fundamental to the objectives of the Common Market) 
is increasingly taking precedence over the principles of IP rights, such as the 
territorial exhaustion of rights. Reliance on IP rights and the territoriality 
thereof creates conflict with the free movement of goods principle. Patentees 
who have tried to rely on their exclusive importation right to prevent parallel 
imports. have found that the European Court of Justice (ECj) is increasingly 
placing reliance on provisions of the EC Treaty (the so-called Treaty of 
Rome). such as Articles 85 and 30-36, to remove impediments to parallel 
imports and to promote Free movement of goods. 
i 3 SeCllon 20(2) of the Designs Act has a similar provision 










































LAW, DEMOCRACY & DEVELOPMENT 
Another example of the globalisation effect is to be found in TRIPS itself. 
In the preamble to TRIPS, the desire is expressed to reduce distortions and 
impediments to international trade, and to ensure that measures and 
procedures used to enforce intellectual property rights do not themselves 
become barriers to legitimate trade. TRI PS itself, however, does not address 
the issue of the exhaustion of intellectual property rights (Article 6). And 
where provision is made in Article 28 for an importation right to be con-
ferred by a patent, this right is made subject to the exclusionary provision 
relating to exhaustion. 
8 RECENT SOUTH AFRICAN MEDICINES LEGISLATION 
Parliament passed, in November 1997, the controversial Medicines and 
Related Substances Control Amendment Act 90 of 1997.15 The Amendment 
Act was controversial for a number of reasons, but from the intellectual 
property perspective IP practitioners were concerned about an apparent 
attempt to override IP rights. 
In the Amendment Act, the objectives are stated to be to amend the 
Principal Act, that is the Medicines and Related Substances Control Act 101 
of 1965,10 inter alia to make further provision for the prohibition of the sale 
of medicines which are subject to registration and are not registered; to 
provide procedures that will expedite the registration of essential medicines, 
and to provide for the re-evaluation of all medicines after five years; to 
proVide for measures for the supply of more affordable medicines in certain 
circumstances; to provide for the licensing of certain persons to compound, 
dispense or manufacture medicines; and to provide for generic substitution 
of prescribed medicines. 
All of these objectives are accepted to be legitimate and in fact necessary 
in order to provide the necessary machinery to implement government 
policy, namely to ensure that the entire population should have access to 
affordable health care and value-for-money medicinal products. However, 
in creating a legislative and regulatory framework to achieve these objec-
tives, it is important that certain principles should to be adhered to, namely 
those principles contained in, and recognised and enforced by, national 
and international intellectual property laws and treaties. It is in this context 
that serious questions have been raised regarding the Medicines Amendment 
Act. 
15 Published in the Government Gazette 18505 of 12 December 1997. 
16 The Amendment Act ie Act 90 of 1997, was subsequently repealed by the South African 
Medicines Devices Regulatory Authority Act 132 of 1998 (the so-called SAMMDRA Act). with 
the exception of ten sections. one of which is the controversial section 10 which introduced 
section 15C into the Principal Act 101 of 1965. The Principal Act itself was also repealed by 
the SAMMDRA Act. with the exception of seven sections. The SAMMDRA Act was promul-
gated with effect from 30 April 1999, but its promulgation has been set aside in an appeal 
heard by the full bench of the Pretoria High Court case A819i99. The previous Act 101 of 
1965. as it applied on 29 April 1999. was reinstated. See Government Notice R977 of 13 
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The most controversial provision was contained in section 10 of the 
Amendment Act. which sought to insert a new section 15C into the Principal 
Act. as follows: 
"Measures to ensure supply of more affordable medicines 
15C. The MInister may prescribe conditions for the supply of more affordable 
medicines in certain circumstances so as to protect the health of the public, 
and in particular may -
(a) notwithstanding anything to the contrary contamed in the Patents Act, 
1978 (Act no. 57 of 1978). determine that the rights with regard to 
any medicine under a patent granted in the Republic shall not extend 
to acts m respect of such medicine which has been put onto the mar-
ket by the owner of the medicine. or with his or her consent: 
(b) prescribe the condItions on which any medicine which is Identical in 
composition, meets the same quality standard and is intended to have 
the same proprietary name as that of another medicine already regiS-
tered In the Republic. but which is imported by a person other than 
the person who is the holder of [he registration certificate of the 
mediCIne already registered and which originates from any site of 
manufacture of the original manufacturer as approved the council 
In the prescribed manner, may be imported; 
(Cl prescribe the registration procedure for, as well as the use of. the 
medicine referred to in paragraph (bl" 
It will be noted from the introductory part of section 15C. that the authority 
given to the Minister (of Health) is expressly stated to prescribe conditions for 
the supply of more affordable medicines in certain circumstances. so as to 
protect the health of the public. 
The provisions of section 15C were interpreted by the pharmaceutical 
industry as empowering the Minister to be in a position to override patent 
and trade mark rights at any time by mere administrative action. This was 
viewed as being contrary to South Africa's imernational obligations in terms 
of the TRIPS Agreement. namely that patented inventions in all fields of 
technology are to be given full patent protection. subject only to the 
limitations as set out in TRI PS itself 17 
Article 27 of TRIPS provides that patents shall be available for all inven-
tions, whether products or processes. in all fields of technology. and patent 
rights shall be enjoyable without discrimination as to the place of invention. 
the field of technology and whether products are imported or produced 
locally. Article 28 confers on the patentee I owner of the patent the exclusive 
rights already set out above. including the exclusive right to prevent third 
parties from importing. using, selling or offering for sale the patented 
product. These two provisions, when read together. are interpreted as 
meaning that a curtailment of the exclusive rights in the case of patents in 
a particular field of technology. as enVisaged in section 15C(a). would 
amount to discrimination as regards the enjoyment of patent rights in 
contravention of Article 27. 










































LAW, DEMOCRACY & DEVELOPMENT 
It has to be taken into account that TRIPS itself makes provision for certain 
exceptions to or limitations on patent rights. For instance, Article 8.1 permits 
member countries to adopt measures necessary to protect public health, 
provided such measures are consistent with the provisions of TRIPS. Article 
8.2 permits member countries to adopt measures to prevent the abuse of 
intellectual property rights, provided such measures are consistent with the 
other provisions of TRIPS. The proviso appearing in Articles 8.1 and 8.2. 
namely that any measures adopted should be consistent with TRIPS itself. is 
viewed as an uncompromisable requirement. 
Article 30 also expressly states that member countries may provide for 
limited exceptions to the exclusive rights conferred by a patent. again subject 
to the proviso that such exceptions do not unreasonably conflict with the 
normal exploitation of the patent and do not unreasonably prejudice the 
legitimate interests of the patent owner, taking into account the legitimate 
interests of third parties. 
Article 31 sets out in particularity the principles and directives to be 
respected where a member country allows for the use of the subject matter 
of a patent without the authority of the patent owner, including use by the 
government or third parties authorised by the government. The framework 
set out in Article 31 is viewed as a fair and workable mechanism inasmuch 
as a number of checks and balances have been provided for, such as that: 
• use by third parties must be considered on individual merit; 
• efforts must first be made to obtain authorisation from the patentee on 
reasonable commercial terms; 
• the authorised use will be to supply predominantly the domestic market: 
• adequate remuneration is to be paid to the patentee; and 
• the legal validity of the decision must be subject to judicial review. 
The framework contemplated in Article 3 i is generally accepted to be 
embodied in a system of compulsory licences, as provided for in section 56 
of the Patents Act 1978. 
The question then remains to be answered: was there an alternative route 
available to the Minister of Health to achieve the stated objective of more 
affordable medicine? 
It is submitted that the mechanism of compulsory licences, already recog-
nised in the Patents Act. could have been modified to apply in the situation 
concerned. 
The South African Patents Act already contains provisions in section 56 for 
the granting of compulsory licences in circumstances where patent rights are 
abused. These provisions provide a useful framework for a mechanism which 
could have been used to achieve the curtailment of patent rights as appar-
ently envisaged by section 15e(a). The compulsory licence mechanism of 
section 56 is generally in conformity with the provisions of Article 31 of 
TRIPS, where the requirements for use of the subject matter of a patent 
without the authority of the right holder. including use by government or 
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The granting of a compulsory licence in terms of section 56 of the Patents 
Act takes place by way of judicial process, before the Commissioner of 
Patents. A judicial process is not only transparent, but it affords the patentee 
whose rights are to be curtailed, an opportunity to be heard. 
International norms generally favour a judicial process or a subordinate 
legislative process to be used when patent rights are to be curtailed. 
Section 56 contains provisions setting out when patent rights will deem to 
be abused, if for example: 
• the demand for the patented article in the Republic is not being met to an 
adequate extent and on reasonable terms; 
• by reason of the refusal of the patentee to grant a licence on reasonable 
terms the trade of any class of persons is being prejudiced, and it is in the 
public interest that a licence should be granted; 
• the demand for the patented article / product is being met by importation 
and the price charged by the patentee is excessive in relation to the price 
charged in other countries where the product is manufactured by the 
patentee. 
It is known that the pharmaceutical industry initiated court proceedings 
against the Minister of Health and others, and that the Amendment Act has 
not been implemented. It is not unlikely that it will fall away altogether, in 
view of other draft legislation published recently. 
9 PARALLEL TRADING ISSUES FACING AFRICA 
It is my firm conviction that parallel importation issues will become increas-
ingly relevant to the countries of Africa. In my view this will happen for 
several reasons: 
African countries are emerging as new destinations for technology, which 
means that the intellectual property rights relating to the technology will 
require protection. As more countries on the African continent join multiple-
filing systems such as the Patent Co-operation Treaty, the protection of IP in 
African countries will become easier and therefore more attractive. 
That does not mean to say, however, that the IP owners will necessarily 
put up manufacturing operations in all countries where they hold rights. It is 
more than likely that the local demand in individual countries will be met by 
importation. This is entirely in line with TRIPS provisions. 
This means that the scene will be set for parallel traders to see an oppor-
tunity of profit. Particularly in the field of pharmaceuticals, and taking into 
account the enormous need for health care in Africa, this phenomenon is 
likely to occur. Many hold the view that this might ultimately be to the 
benefit of African countries, as a mechanism to suppress elevated price 
structures. 
If parallel importation of pharmaceuticals is to be used to benefit the 
people of Africa, it is essential that an accurate and reliable study should be 
made of all of the aspects outlined above, with particular relevance to the 
countries of Africa. A debate amongst African countries needs to commence. 
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in regard to parallel imports of pharmaceuticals in European countries, and 
from the writings of learned authors on that subject, but the fundamental 
differences between the situation in African countries and that of European 
Community Member States (with the fundamental principle of the free 
movement of goods) should not be overlooked, 
It is suggested that the following aspects need to be taken into account in 
the course of such an African debate: 
• The importance should be recognised of intellectual property rights and 
their appropriate protection, as a means of encouraging innovation and 
creative activity on the African continent, and to encourage foreign tech-
nology to be introduced into Africa. 
• The need should be accepted for African countries to endeavour to bring 
their IP laws in compliance with TRIPS, so that IP owners will be assured 
of the necessary minimum levels of protection and enforcement of rights, 
and so that the playing fields will be levelled. 
• Unfortunately, TRIPS itself does not provide a solution. nor even clear 
guidelines. to the issue of parallel importation and the doctrine of the 
exhaustion of rights. These aspects will have to be assessed, not only 
from an academic point of view but also in practical terms, and workable 
yet fair solutions found. 
• Efforts should be made to encourage pharmaceutical companies to set up 
manufacturing operations in Africa, In the absence of local manufacture 
on the continent, African countries will continue to be the banle ground 
of the foreign IP owner and manufacturer trying to recoup its R&D ex-
penses in addition to generating a profit, and the unscrupulous parallel 
trader who has a profit motive without any interest in adding value to 
services or products, 
• Recognition should be given to the fact that most African countries are in 
need of more affordable and more available medicines. However, at the 
same time it should be confirmed that Africa cannot become the dumping 
ground of poor quality pharmaceutical products, In endeavouring to make 
more medicines available more cheaply, no compromise can be made as 
to quality and purity, 
• An attempt has been made in South Africa in the recent Medicines 
legislation to create a mechanism for more affordable medicines to be 
made available, presumably by way of parallel importation, This legisla-
tion met with forceful opposition by pharmaceutical companies. This is 
not the appropriate opportunity to go into more detail, but my own belief 
is that the same result could have been achieved with less exposure to 
opposition, if a different legal mechanism had been used, Legalising 
parallel importation evoked strong opposition, 
• Finally, the subject of the abuse of IP rights (eg, patent rights in the case 
of pharmaceuticals), needs to be revisited, and clear principles, applicable 
to present circumstances, and in the context of the needs of African 
countries, should be defined, A balance should be attained between the 
adequate protection of IP rights, on the one hand, and the adequate 
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